| Date Filed | Type | Description |
| 08/16/2023 |
4
| PASSERI DANIEL R (CEO) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Bought 3,000 shares
@ $2.86, valued at
$8.6k
|
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/09/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/25/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2023 |
4
| Kiener Peter A (Director) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Sold 9,325 shares
@ $3.28, valued at
$30.6k
Exercised 9,682 options to buy
@ $2.86, valued at
$27.7k
|
|
| 03/21/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/21/2023 |
4
| NASSHORN PATRICIA (Chief Business Officer) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 97,900 options to buy
@ $3.21, valued at
$314.3k
|
|
| 02/21/2023 |
4
| Suri Anish (PRESIDENT AND CSO) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 125,500 options to buy
@ $3.21, valued at
$402.9k
|
|
| 02/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/03/2023 |
SC 13G/A
| STATE STREET CORP reports a 0.3% stake in EXIT FILING CUE BIOPHARMA INC |
| 01/19/2023 |
4
| Levisetti Matteo (Chief Medical Officer) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 110,000 options to buy
@ $3.36, valued at
$369.6k
|
|
| 01/19/2023 |
3
| Levisetti Matteo (Chief Medical Officer) has filed a Form 3 on Cue Biopharma, Inc. |
| 01/05/2023 |
4
| Morich Frank (Director) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
| 01/05/2023 |
4
| Kiener Peter A (Director) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
| 01/05/2023 |
4
| HOWSON TAMAR D (Director) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
| 01/05/2023 |
4
| Fletcher Aaron G.L. (Director) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
| 01/05/2023 |
4
| DRISCOLL FREDERICK W (Director) has filed a Form 4 on Cue Biopharma, Inc.|
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
| 12/30/2022 |
424B7
| Form 424B7 - Prospectus [Rule 424(b)(7)]: |
| 12/15/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/15/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/06/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 12/02/2022 |
SC 13G/A
| Nantahala Capital Management, LLC reports a 0.3% stake in Cue Biopharma, Inc. |
|